| 王 艳,李文慧,司亚娟.复方嗜酸乳杆菌联合含铋剂四联疗法在Hp感染性消化性溃疡中的应用效果分析[J].中国烧伤创疡杂志,2022,(2):145~149. |
| DOI： |
| 中文关键词: 复方嗜酸乳杆菌 含铋剂四联疗法 幽门螺杆菌 消化性溃疡 生存质量 |
| 英文关键词:Compound Eosinophil-Lactobacillus Tablets Bismuth quadruple therapy Helicobacter pylori Pepticulcer Quality of life |
| 基金项目: |
|
| 摘要点击次数: 1607 |
| 全文下载次数: 4633 |
| 中文摘要: |
| 【摘要】 目的 分析探讨复方嗜酸乳杆菌联合含铋剂四联疗法治疗幽门螺杆菌(Hp)感染性消化性溃疡的临床效果。方法 选取2020年1月至2020年12月郑州市第七人民医院收治的100例Hp感染性消化性溃疡患者作为研究对象, 按照随机数表法将其随机分为观察组(50例)与对照组(50例)，观察组患者采用复方嗜酸乳杆菌联合阿莫西林胶囊+奥硝唑片+复方铝酸铋颗粒+雷贝拉唑钠肠溶片的四联疗法治疗，对照组患者单纯采用阿莫西林胶囊+奥硝唑片+复方铝酸铋颗粒+雷贝拉唑钠肠溶片的四联疗法治疗，对比两组患者血清白细胞介素-1(IL-1)、白细胞介素-6 (IL-6)、C反应蛋白(CRP)水平以及生存质量与焦虑、抑郁评分变化情况。结果 治疗2 周后，观察组患者IL-1、IL-6及CRP水平均明显低于对照组(t=7.949、6.913、9.987，P均＜0.001)；治疗结束后3个月随访时，观察组患者世界卫生组织生存质量测定量表简表(WHOQOL-BREF)各评分均明显高于对照组(t =5.132、5.290、4.687、6.182，P均＜0.001)， 焦虑自评量表(SAS)与抑郁自评量表(SDS)评分均明显低于对照组(t =15.730、11.503，P均＜0.001)。结论 与单纯应用含铋剂四联疗法相比，复方嗜酸乳杆菌联合含铋剂四联疗法可明显减轻Hp感染性消化性溃疡患者的炎症反应，提高患者生存质量，缓解患者焦虑抑郁情绪。 |
| 英文摘要: |
| 【Abstract】 Objective To study the clinical efficacy of Compound Eosinophil-Lactobacillus Tablets combined with Bismuth quadruple therapy (BQT) in the treatment of peptic ulcer induced by Helicobacter Pylori (Hp).Methods 100 patients with Hp-induced peptic ulcer, admitted into The 7th People’s Hospital of Zhengzhou between January 2020 and December 2020, were enrolled as research subjects, and divided into observation group(n=50) and control group (n =50) using the random number table. Patients in observation group were treated with Compound Eosinophil-Lactobacillus Tablets combined with Bismuth quadruple therapy (BQT)-Amoxicillin Capsules + Ornidazole Tablets + CompoundBismuth Aluminate Granules + Rabeprazole Sodium Enteric-coated Tablets, whereas patients in control group were treated with Bismuth quadruple therapy (BQT) only. Changes of serum interleukin-1(IL-1), interleukin-6), C-reaction protein (CRP), quality of life, and anxiety and depression score were compared between the two groups. Results 2 weeks after treatment, the levels of IL-1, IL-6 and CRP in observation group were all remarkably lower than control group (t =7.949, 6.913 and 9.987, all P <0.001). The follow-up 3 months after treatment found that WHOQOL-BREF scores of pa-tients in observation group were all obviously higher than control group (t = 5.132, 5.290, 4.687 and 6.182, all P <0.001), while the self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores were significantly lower than control group (t =15.730 and 11.503, both P < 0.001). Conclusion Compared with the application of BQT, the combined application of Compound Eosinophil-Lactobacillus Tablets and BQT in the treatment of Hp-induced peptic ulcer can significantly relieve patients’ inflammatory reactions, improve their quality of life and ameliorate their anxiety and depression. |
|
|
|
|
